Literature DB >> 18239069

Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway.

Travis Pew1, Min Zou, Deanna R Brickley, Suzanne D Conzen.   

Abstract

The glucocorticoid receptor (GR) and its ligand, cortisol, play a central role in human physiology. The exact mechanisms by which GR activation regulates these processes are the subject of intensive investigation. We and others have shown that GR activation can indirectly down-regulate specific genes via serum and glucocorticoid (GC) regulated kinase-1-mediated inhibition of forkhead box O3a (FOXO3a) transcriptional activity. We previously used gene expression microarrays, together with bioinformatic analyses, to identify putative FOXO3a target genes in breast epithelial cells. In this paper we refine our analysis through the use of FOXO3a chromatin immunoprecipitation (ChIP) microarrays. ChIP microarray results reveal urokinase plasminogen activator (uPA) as a putative novel target of FOXO3a in breast epithelial and breast cancer cell lines. We further show that uPA down-regulation after GC treatment requires serum and GC regulated kinase-1-mediated inactivation of FOXO3a activity. ChIP and luciferase assays confirm that FOXO3a can both occupy and transactivate the uPA promoter. Our data suggest that inactivation of FOXO3a after GR activation is an important mechanism contributing to GC-mediated repression of uPA gene expression in breast epithelial and cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239069      PMCID: PMC2329267          DOI: 10.1210/en.2007-1096

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  39 in total

1.  Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.

Authors:  N Busso; D Belin; C Failly-Crépin; J D Vassalli
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

2.  Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes.

Authors:  N Busso; M Collart; J D Vassalli; D Belin
Journal:  Exp Cell Res       Date:  1987-12       Impact factor: 3.905

Review 3.  The urokinase-type plasminogen activator system in cancer metastasis: a review.

Authors:  P A Andreasen; L Kjøller; L Christensen; M J Duffy
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

4.  Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum.

Authors:  M K Webster; L Goya; Y Ge; A C Maiyar; G L Firestone
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

5.  The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.

Authors:  S G Kennedy; A J Wagner; S D Conzen; J Jordán; A Bellacosa; P N Tsichlis; N Hay
Journal:  Genes Dev       Date:  1997-03-15       Impact factor: 11.361

6.  Glucocorticosteroids inhibit degradation in bovine cartilage explants stimulated with concomitant plasminogen and interleukin-1 alpha.

Authors:  A J Augustine; J Oleksyszyn
Journal:  Inflamm Res       Date:  1997-02       Impact factor: 4.575

7.  Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity.

Authors:  C Nerlov; P Rørth; F Blasi; M Johnsen
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

8.  Regulation of plasminogen activator activity in arthritic joints.

Authors:  J A Hamilton; P H Hart; T Leizer; G F Vitti; I K Campbell
Journal:  J Rheumatol Suppl       Date:  1991-02

9.  Modulation of urokinase-type plasminogen activator messenger RNA levels in human synovial fibroblasts by interleukin-1, retinoic acid, and a glucocorticoid.

Authors:  G Vitti; J A Hamilton
Journal:  Arthritis Rheum       Date:  1988-08

10.  Plasminogen activators in synovial fluid and plasma from patients with arthritis.

Authors:  E J Brommer; G Dooijewaard; B A Dijkmans; F C Breedveld
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

View more
  4 in total

1.  Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.

Authors:  Ben A Hall; Tae Yeon Kim; Maxwell N Skor; Suzanne D Conzen
Journal:  Breast Cancer Res Treat       Date:  2012-07-29       Impact factor: 4.872

2.  Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.

Authors:  Victoria Stepanova; Konstantin V Dergilev; Kelci R Holman; Yelena V Parfyonova; Zoya I Tsokolaeva; Mimi Teter; Elena N Atochina-Vasserman; Alla Volgina; Sergei V Zaitsev; Shane P Lewis; Fedor G Zabozlaev; Kseniya Obraztsova; Vera P Krymskaya; Douglas B Cines
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

3.  Adaptive variation regulates the expression of the human SGK1 gene in response to stress.

Authors:  Francesca Luca; Sonal Kashyap; Catherine Southard; Min Zou; David Witonsky; Anna Di Rienzo; Suzanne D Conzen
Journal:  PLoS Genet       Date:  2009-05-22       Impact factor: 5.917

4.  AMPK Mediates Glucocorticoids Stress-Induced Downregulation of the Glucocorticoid Receptor in Cultured Rat Prefrontal Cortical Astrocytes.

Authors:  Shi-Ying Yuan; Jue Liu; Jun Zhou; Wei Lu; Hai-Yun Zhou; Li-Hong Long; Zhuang-Li Hu; Lan Ni; Yi Wang; Jian-Guo Chen; Fang Wang
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.